Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
This study is ongoing, but not recruiting participants.
Study NCT00059631   Information provided by M.D. Anderson Cancer Center
First Received: April 29, 2003   Last Updated: February 17, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostate Cancer
Additional conditions recognized in this trial
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
Mitoxantrone (Novantrone)
Bortezomib (PS-341)
Additional drug interventions recognized in this trial
Bortezomib
Mitoxantrone
More general drug interventions related to this trial
Analgesics
Antineoplastic Agents
Central Nervous System Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services